Oppenheimer Sees Upside in Shares of Jazz Pharmaceuticals (JAZZ)
Tweet Send to a Friend
Oppenheimer reiterated an Outperform rating on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a price target of $66.00.
“We recently hosted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
“We recently hosted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
